Abstract. The novel bromophenol derivative, 3-(3-bromo-5-me thoxy-4-(3-(piperidin-1-yl)propoxy)benzylidene)-N-(4-bromoph enyl)-2-oxoindoline-5-sulfonamide (BOS-93), was synthesized in the CAS Key Laboratory of Experimental Marine Biology, Institute of Oceanology, Chinese Academy of Sciences (Qingdao, China). Experimental studies have demonstrated that it could induce apoptosis and autophagy in human A549 lung cancer cells, and it could also inhibit tumor growth in human A549 lung cancer xenograft models. In the present study, the molecular pathways underlying these effects were identified. The results demonstrated that BOS-93 could inhibit cell proliferation in A549 cells and block A549 cells at the G0/G1 phase. Furthermore, BOS-93 could induce apoptosis, activate caspase-3 and poly ADP ribose polymerase, and increase the B cell lymphoma (Bcl)-2 associated X protein/Bcl-2 ratio. Notably, BOS-93 could also induce autophagy in A549 cells. BOS-93-induced autophagy was confirmed by detecting light chain 3 (LC3)-I/LC3-II conversion and increasing expression of beclin1 and autophagy-related gene 14. Notably, BOS-93-induced autophagy could be inhibited by the autophagy inhibitor 3-MA. Flow cytometry, transmission electron microscopy (TEM) and western blot analysis indicated that BOS-93 induced apoptosis and autophagy activities by deactivating phosphoinositide 3-kinase/protein kinase B/mechanistic target of rapamycin and activating the mitogen-activated protein kinase signaling pathway. The present findings indicated that BOS-93 might be a novel anti-cancer agent for treatment of human lung cancer.
Introduction
Bromophenols, a unique type of compound derived from marine sources, are mainly isolated from marine fungi, marine algae, sponges, ascidians, and bryozoans (1, 2) . It is difficult to separate natural bromophenols from marine organisms, and they often exhibit low biological activity (3) (4) (5) . However, bromophenol derivatives exhibit excellent biological activity, including anti-oxidation, antibacterial and anti-tumor activities (3, 4) . In our previous study, a series of bromophenol compounds were designed. This series of compounds exhibited excellent antitumor activities and could inhibit the growth of a variety of tumor cells (6) . One of these compounds, 3-(3-bromo-5-metho xy-4-(3-(piperidin-1-yl)propoxy)benzylidene)-N-(4-bromophen yl)-2-oxoindoline-5-sulfonamide (BOS-93; Fig. 1A ), exhibited significant anti-tumor activities. Notably, in the present study, it was demonstrated to induce autophagy in A549 cells, unlike the mechanisms of the compounds we previously reported.
Apoptosis is the autonomous, orderly death of cells controlled by genes to maintain homeostasis. It mainly comprises two representative pathways: The mitochondrial pathway, which is the major pathway, and the death receptor-mediated pathway (7) . Reactive oxygen species (ROS) also serve a critical role in the mitochondrial pathway; generation of ROS can induce mitochondrial membrane damage, releasing cytochrome c from injured mitochondria and thereby inducing cell apoptosis (8) .
Autophagy, also known as type II cell death, is the process by which cells use lysosomes to degrade their own damaged organelles and macromolecules under the control of autophagy-related genes (Atg) (9) . Apoptosis and autophagy are the molecular mechanisms by which cells maintain organelles and homeostasis. Although autophagy can also lead to cell death under certain conditions, it primarily maintains a constant state in a cell through selective reutilization of organelles and macromolecules (10, 11) .
Autophagy begins with the production of double-membrane vacuoles (named autophagosomes) that entrap the material to be degraded and eventually fused with lysosomes (12 Autophagosomes are characterized by the presence of the protein light chain 3 (LC3) (derived from posttranslational modifications of a microtubule-associated protein precursor) on their membranes. Beclin-1, which was initially isolated as an interactor of the oncogenic anti-apoptotic protein among many proteins that directly or indirectly regulate the autophagy process (12, 13) . In eukaryotes, autophagy is an important process that is evolutionarily reserved for turnover of intracellular material (13) . The mammalian target of rapamycin (mTOR) signaling pathway, and the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt)/mTOR pathway in particular, is associated with most physiological processes, including cell metabolism, proliferation and autophagy (14, 15) .
In the present study, the mechanism underlying the anticancer effects of BOS-93 in A549 lung cells was investigated. The results demonstrated that BOS-93 could induce apoptosis and cause autophagy in A549 cells. In addition, the molecular mechanisms underlying BOS-93-induced apoptotic and autophagic death in A549 cells were investigated. Further studies indicated that the PI3K/Akt/mTOR and p38/extracellular signal-regulated kinase signaling pathways were associated with BOS-93-induced apoptosis and autophagy. In summary, the present results indicated that BOS-93 may be a promising anti-tumor drug against human lung cancers.
Materials and methods
Reagents, chemicals and antibodies. BOS-93 was synthesized by the CAS Key Laboratory of Experimental Marine Biology, Institute of Oceanology, Chinese Academy of Sciences, (Qingdao, China; purity >98%) (6) . The purity of compound BOS-93 was measured by high-performnce liquid chromatography (HPLC; Shimadzu Corporation, Kyoto, Japan), carried out on a Shimadzu LC-20A system (Shimadzu Corporation) equipped with a Shimadzu InertSustain C-18 reverse phase column (4.6x250 x5 µm; Shimadzu Corporation) and SPD-20A detector (Shimadzu Corporation). HPLC was conducted at 25˚C with 70% methanol and 50% acetonitrile mobile phases. The flow rate was 1 ml/min and samples were 10 µl. The F-12K and RPMI-1640 mediums were obtained from Hyclone; GE Healthcare Life Sciences (Logan, UT, USA), fetal bovine serum (FBS) was obtained from ExCell Bio, Inc., (Shanghai, China), other culture reagents were purchased from Invitrogen; Thermo Fisher Scientific, Inc., ( Cell line and culture. Cells (A549, 95D and NCI-H460) were purchased from Cell Bank, Chinese Academy of Sciences (Shanghai, China). A549 cells were maintained in F-12K medium, whereas 95D cells and NCI-H460 cells were maintained in RPMI-1640 medium, and all mediums were supplemented with 10% FBS, 100 U/ml penicillin and 100 µg/ml streptomycin. Cells were cultured at 37˚C in a humidified CO 2 (5%) atmosphere.
Determination of cell viability. Cell viability was determined via MTT assay. Cells in growth phase were plated into 96-well plates at a density of 3x10 3 cells per well and incubated for 24 h. Then, cells were exposed to 0, 2.5, 5, 10 and 20 µg/ml BOS-93 for 48 h. Following treatment, cells were further incubated with MTT for 4 h. Then the formazan was dissolved by dimethyl sulfoxide and measured using a microplate reader at 490 nm. The 50% inhibitory concentration (IC 50 ) was defined as the concentration that reduced the absorbance of the untreated wells by 50% of the vehicle in the MTT assay.
Colony formation assay. A549 cells were harvested and 500 cells/well were seeded in 6-well plates and allowed to settle overnight at 37˚C. Then cells were treated with BOS-93 (0, 2.5, 5 and 10 µg/ml) at 37˚C for 10 days. Following treatment, cells were washed with PBS and fixed with 4% paraformaldehyde at room temperature for 10 min. Cells were washed with PBS and finally stained with crystal violet at room temperature for 10 min. Cells were scored under light microscopy (magnification, x100) and >50 cells clustered together were scored as colonies (16) .
Apoptosis assay by flow cytometry. Apoptosis was determined by flow cytometry. Briefly, cells (1x10 5 cells/well) were seeded in 6-well plates and allowed to settle overnight at 37˚C, and then cells were treated with BOS-93 (0, 2.5, 5 and 10 µg/ml) for 48 h. Cells were harvested and stained with Annexin V-fluorescein isothiocyanate (FITC) and propidium iodide (PI; Beyotime Institute of Biotechnology, Haimen, China) at room temperature for 15 min, then cells were analyzed using a flow cytometer (BD FACSCalibur) and CellQuest Pro software (FACSstation 6.0; BD Biosciences, Franklin Lakes, NJ, USA).
Cell cycle analysis. Cell cycle analysis was determined by flow cytometry. Briefly, A549 cells (1x10 5 cells/well) were harvested and seeded in 6-well plates and allowed to settle overnight at 37˚C. Cells were treated with BOS-93 (0, 2.5, 5 and 10 µg/ml) at 37˚C. Following 48 h treatment, cells were harvested and fixed in 7% ethanol at -20˚C overnight. Cells were washed twice with PBS and stained with PI solution containing 20 µg/ml RNaseA and 50 µg/ml PI (both Beyotime Institute of Biotechnology) at 37˚C for 30 min. Then cells were analyzed using flow cytometry and CellQuest Pro software.
Hoechst 33258 staining. The cell nucleus shape was observed by fluorescence microscopy following Hoechst 33258 staining. Briefly, cells (1x10 5 cells/well) were seeded in 6-well plates and allowed to settle overnight at 37˚C, and then cells were treated with BOS-93 (0, 2.5, 5 and 10 µg/ml) at 37˚C for 48 h. Following treatment, cells were stained with Hoechst dye 33258 for 5 min at room temperature and assessed by fluorescence microscopy (magnification, x400; Olympus Corporation, Tokyo, Japan).
Transmission electron microscopy. A549 cells were exposed to BOS-93 (10 µg/ml) for 48 h at 37˚C and cells were fixed in 2.5% glutaraldehyde (Shanghai Yuanye Biotechnology Co., Ltd., Shanghai, China) overnight at 4˚C and postfixed with 1% osmium tetroxide (OsO 4 ) and kaliumhexacyanoferrate [K 3 FE(CN) 6 ] in cacodylate buffer. Subsequently, the cells were dehydrated in an alcohol series and embedded in resin overnight at room temperature. Ultrathin sections (200 nm) were collected on formvar-coated grids, counterstained with uranil acetate and lead citrate at room temperature for 10 min, and visualized with transmission electron microscopy (TEM; JEM-1200EX, JEOL Ltd., Akishima, Japan; magnification, x8,000).
Analysis of cells with GFP-LC3.
To detect GFP-LC3 translocation, A549 cells (1x10 5 cells/ml) were grown on glass coverslips at 37˚C for 24 h and then infected with Ad-GFP-LC3 (Beyotime Institute of Biotechnology). Following overnight culture at 37˚C, cells were treated with BOS-93 (10 µg/ml) at 37˚C for 48 h. Then cells were fixed with 4% paraformaldehyde at 37˚C for 20 min and examined under a fluorescence microscope (magnification, x400).
Analysis of autoghagy with 3-MA.
The autophagy inhibitor 3-MA was also used to block autophagy at the final concentration of 5 mM. Briefly, A549 cells (1x10 5 cells/well) in a 6-well plate were pretreated with 3-MA (5 mM) at 37˚C for 1 h, and then cells were treated with BOS-93 (0, 2.5, 5 and 10 µg/ml) at 37˚C for 48 h. Cell lysates were detected by western blotting.
Measurement of intracellular ROS.
The measurement of ROS was determined by flow cytometry. A549 cells (1x10 5 cells/well) were harvested and seeded in 6-well plates and allowed to settle overnight at 37˚C. Cells were treated with BOS-93 (0, 2.5, 5 and 10 µg/ml) for 48 h at 37˚C. The medium was removed and cells were co-incubated with 10 µM 2',7'-dichlorofluorescein diacetate (DCFH-DA; Beyotime Institute of Biotechnology) at 37˚C for 30 min. Then cells were harvested and analyzed by flow cytometry and CellQuest Pro software.
Western blot analysis. A549 cells were harvested and seeded in 6-well plates (1x10 5 cells/well) and allowed to settle overnight at 37˚C. Cells were treated with BOS-93 (0, 2.5, 5 and 10 µg/ml) for 48 h at 37˚C. Proteins were harvested by RIPA buffer (Beijing Solarbio Science & Technology Co., Ltd., Beijing, China) and separated by SDS-PAGE on a 10% gel and transferred onto polyvinylidene difluoride membranes. Membranes were blocked in blocking solution (containing 5% non-fat milk) at room temperature for 1 h and subsequently probed with primary antibodies at 4˚C overnight. Following 15 min washes in TBS-Tween 20, the membranes were incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies (cat. no. 7074; 1:10,000; Cell Signaling Technology, Inc.) for 1 h at room temperature. The bands were detected using an enhanced chemiluminescence system BeyoECL Plus (Beyotime Institute of Biotechnology).
In vivo tumor model. Female congenital athymic BALB/c nude (nu/nu) mice (n=12) were purchased from Model Animal Research Center Of Nanjing University (Nanjing, China). Mice were housed in a specific pathogen-free room with controlled temperature (24±2˚C), humidity (60-80%) and lighting (12 h light/dark cycle) with ad libitum access to water and food. All experiments with mice were approved by Institute of Oceanology, Chinese Academy of Sciences Laboratory Animal Care and Ethics Committee (Qingdao, China) in accordance with the animal care and use guidelines. Efforts were made to minimize animal suffering. All experiments were carried out using 6-8-week-old mice weighting 18-22 g. Mice were given 1 week to acclimatize to the housing conditions prior to experiments. In vitro cultured A549 cancer cells (1x10 7 ) were injected subcutaneously into the back of mice. When the tumor reached 150 mm 3 in volume, animals were divided randomly into two groups (n=6 each) and administered with 50 mg/kg intraperitoneal BOS-93 (dissolved in 0.5% carboxymethyl cellulose-Na) for 21 days (once a day). Tumor volumes and body weight were measured every 3 days. Tumor volumes were calculated according to the following equation: Length x (width) 2 /2. Body weight was measured every three days and clinical symptoms were observed daily. Following treatment, mice were anaesthetized with isoflurane (inhalation anesthesia; Shanghai Yuanye Biotechnology Co., Ltd., Shanghai, China) and sacrificed by decapitation and tumor tissues were collected for immunohistochemistry, and haematoxylin and eosin (H&E) analysis.
Immunohistochemistry and H&E staining. Tumor tissues were obtained, immediately fixed in 10% neutral formaldehyde at room temperature for 24 h and later embedded in paraffin wax. The paraffin-embedded tissue sections (4 µm) were treated with heat-induced antigen retrieval buffer (pH 6.0; citrate buffer; Beyotime Institute of Biotechnology) and blocked using 5% bovine serum albumin (Beijing Solarbio Science & Technology Co., Ltd.) at room temperature for 1 h. 
For H&E staining, samples were stained with hematoxylin for 10 min at room temperature. Samples were washed with water for 10 min at room temperature and then stained with eosin for 2 min at room temperature. Samples were observed under a light microscope (magnification, x200).
Statistical analysis. Statistical analysis was performed using GraphPad Prism 5.0 (GraphPad Software, Inc., La Jolla, CA, USA). All data are presented as mean + standard deviation. Differences were analysed with one-way analysis of variance followed by Tukey's post hoc test. The difference between the control and model groups was analysed using Student's t-test. P<0.05 was considered to indicate a statistically significant difference.
Results

BOS-93 inhibits cell proliferation.
Cell viability was detected by MTT assay. As presented in Fig. 1B , BOS-93 had a dose-dependent inhibitory effect on three human lung cancer cells including A549, 95D and NCI-H460 cells. The IC 50 value of BOS-93 on the three cells was 4.78±0.56, 9.99±1.81 and 6.14±0.60 µg/ml, respectively. The effect of BOS-93 on the relative colony formation ability of A549 cells was also investigated. As presented in Fig. 1C and D, the clonogenicity of A549 cells was reduced in a dose-dependent manner following exposure to BOS-93.
BOS-93 induces G0/G1 cell cycle arrest.
The cell cycle progression of A549 cells was analyzed via flow cytometry. A549 cells were analyzed by flow cytometry following treatment with BOS-93 (0, 2.5, 5 and 10 µg/ml) for 48 h. As presented in Fig. 2A and B, following treatment with BOS-93, the accumulation of cells in the G0/G1 phase was increased in a dose-dependent manner. The percentage of cells in the 0, 2.5, 5 and 10 µg/ml groups at the G0/G1 phase was significantly enhanced from 47.54±10.55 to 55.02±7.8, 62.89±9.30 and 72.90±5.80%, respectively.
Western blotting was used to analyze cell cycle associated proteins. As presented in Fig. 2C , following treatment with BOS-93, protein levels of cyclin D1 and CDK4 were decreased, these data indicated that BOS-93-mediated cell cycle arrest at the G0/G1 phase may inhibit the formation of CDK/cyclin complexes via downregulation of cyclin D1 and CDK4.
BOS-93 induces A549 apoptosis.
Apoptosis is a major form of cell death induced by chemotherapeutic agents (17) . In the present study, A549 cells were treated with BOS-93 for 48 h. Cells were stained with Annexin-V-FITC/PI and analyzed by flow cytometry. The results indicated a dose-dependent increase in the proportion of cells in which apoptosis was induced by BOS-93. The apoptotic cell rate in the 0, 2.5, 5 and 10 µg/ml groups were increased from 10.67±1.96 to 17.66±1.72, 31.66±7. 16 and 46.63±8.34%, respectively (Fig. 3A and B) .
Morphological changes in A549 cells were also detected with the Hoechst 33258 staining method. Apoptotic features such as nuclear shrinkage and chromatin condensation were observed, as presented in Fig. 3C . These results demonstrated that BOS-93 could induce apoptosis in A549 cells.
Several classic markers of apoptosis (Bax, Bcl-2, cleaved-caspase3 and cleaved-PARP) were detected by western blot analysis. The results demonstrated that BOS-93 could induce apoptosis via mitochondrial pathways. As presented in Fig. 3D , the expression levels of Bax were increased in BOS-93 treated cells, whereas expression levels of Bcl-2 were decreased. Furthermore, as the concentration of BOS-93 increased, the levels of cleaved caspase-3 and cleaved-PARP were increased (Fig. 3D) . (Fig. 3A) , it was determined that BOS-93 could induce autophagy in A549 cells. A549 cells were treated with BOS-93 for 48 h and evaluated by transmission electron microscopy. As presented in Fig. 4A , marked autophagic characteristics appeared in A549 cells following treatment with BOS-93. Autophagic vacuoles were detected by transmission electron microscopy. GFP-LC3 was used to detect the formation of autophagic vesicles. A549 cells were infected with recombinant adenoviral vector carrying GFP-tagged LC3, and then cells were examined under a fluorescence microscope. As presented in Fig. 4B , GFP-LC3 exhibited diffuse expression in untreated cells, whereas high punctate expression was observed in cells treated with BOS-93.
BOS-93 induces autophagy in A549 cells. Following observing that BOS-93 induced apoptosis
Another notable hallmark of autophagy is the conversion of LC3; specifically, the conversion of LC3-I (18 kDa) to LC3-II (16 kDa), which can be measured by western blot analysis (14) . As presented in Fig. 4B , an increasing ratio of LC3-II/LC3-I was detected following treatment of BOS-93 for 48 h (Fig. 4C) . Notably, the LC3-II/LC3-I ratio was decreased in the presence of the autophagy inhibitor, 3-MA (Fig. 4D) .
Western blot analysis was used to examine the expression of autophagy-related proteins. As presented in Fig. 5A , the expressions of Atg14 and beclin-1 were increased in a concentration-dependent manner following treatment of BOS-93 for 48 h. Furthermore, the content of these proteins was decreased in the presence of 3-MA (Fig. 5B) . These results indicated that A549 cells treated with BOS-93 were undergoing autophagy.
It has been reported that the PI3K/Akt/mTOR signaling pathway serves a major role in regulating autophagy in cancer cells (15) . A549 cells were treated with BOS-93 (2.5, 5, and 10 µg/ml) for 48 h, and the associated proteins were analyzed using western blot analysis. As presented in Fig. 5C , treating A549 cells with BOS-93 for 48 h resulted in decreased phosphorylation of PI3k, Akt and mTOR.
BOS-93 stimulates ROS generation in A549 cells.
The level of intracellular ROS was quantitatively estimated using a peroxide-sensitive fluorescent probe, DCFH-DA, and analyzed by flow cytometry. Compared with the control group, ROS was rapidly produced following exposure to A549 cells with BOS-93 ( Fig. 6A and B) . When treated with BOS-93 for 48 h, the mean DCF fluorescence in the 2.5, 5 and 10 µg/ml groups was increased by 279.38±71.23, 384.01±21.60 and 440.80±40.04%, respectively.
BOS-93 induces autophagy and apoptosis in A549 cells through ROS-dependent ERK and P38 MAPK activation.
It has been reported that the activation of MAPKs, such as ERK and p38 MAPK, is associated with regulation of apoptosis and autophagy (15) . A549 cells were treated with BOS-93 (2.5, 5, and 10 µg/ml) for 48 h, and the expression levels of ERK and p38 MAPK were analyzed by western blot analysis. As presented in Fig. 6C , following treatment of BOS-93, the phosphorylation of p-p38 and p-ERK was increased. These findings indicated that BOS-93 could induce apoptosis and autophagy in A549 cells via the ROS-mediated PI3K/Akt/mTOR and MAPK signaling pathways.
BOS-93 inhibits tumor growth in the in vivo A549
cell xenograft model. In order to evaluate the anti-tumor properties of BOS-93 in vivo, an A549 xenografted athymic mice mode was established in the present study. As presented in Fig. 7A , the tumor growth was markedly inhibited in the BOS-93 treated group at an inhibition ratio of 47.93%. Furthermore, there was no significant change in mice body weight during the experiment (Fig. 7B) . For histological analysis, the heart, spleen and kidney were stained with hematoxylin and eosin, as presented in Fig. 7C , and there were no marked histological changes in these tissues following treatment with BOS-93, these results may suggest that the anti-tumor activity of BOS-93 has low toxicity on athymic mice.
It was further demonstrated that BOS-93 induced apoptosis and autophagy in vivo. Immunohistochemistry with Ki 67 (a cell proliferation marker) and LC3B (a cell autophagy marker) were examined in paraffin-embedded tumor sections. As present study, cell cycle analysis demonstrated that BOS-93 could induce G0/G1 cell cycle arrest in A549 cells. It is well known that cyclin-dependent kinases serve an important role in cell cycle regulation (19) . Additionally, BOS-93 induces G0/G1 cell cycle arrest by inhibiting the activity of cyclin-dependent kinases cyclin D1 and CDK 4 (20) . The present study indicated that BOS-93 could exert its anti-proliferative effect via the modulation of cyclin-CDK machinery-mediated cell-cycle arrest.
Apoptosis serves a key role in the regulation of cells. It mainly comprised two apoptotic pathways: The death receptor-mediated apoptosis pathway and the mitochondria-mediated apoptosis pathway (21) . In the latter, proteins from the Bcl-2 family, such as Bax and Bcl-2, are the main components that regulate mitochondrial permeability. The implementation of apoptosis is achieved through a proteolysis chain reaction comprising, for example, the caspase family (22) . In the present study, it was demonstrated that BOS-93 treatment could increase the ratio of Bax/Bcl-2 as well as activate caspase-3 and PARP. These results indicated that BOS-93 could activate the mitochondrial apoptotic pathway in A549 cells. In addition, it has been reported that ROS serves a key role in the process of mitochondria-mediated apoptosis (23) . In the present study, an increase in ROS generation was observed in cells treated with BOS-93, indicating that ROS serves an important role in BOS-93-induced apoptosis.
In research on chemotherapeutic drugs, apoptosis is commonly considered to be a prevailing anti-cancer mechanism (24) (25) (26) . However, apoptosis is not the only such mechanism; other forms of cell death, such as autophagy, can also occur (27) . When autophagy occurs, certain morphological characteristics, such as autophagosomes, can be observed by TEM (28) . Notably, TEM also revealed that BOS-93 induces cell autophagy.
Microtubule-associated protein LC3 is a cytoplasmic protein that is quickly cleaved to form LC3-I (18 kDa) (29) . It is activated by lipidation with phosphatidylethanolamine to form LC3-II (16 kDa), and the amount of LC3-II is correlated with the number of autophagosomes (29) . The conversion of LC3-I (18 kDa) to LC3-II (16 kDa) typically corresponds to an increase in the rate of autophagy (28, 30) . In the present study, TEM was used to detect the effect of BOS-93 on the ultrastructure of A549 cells. Following BOS-93 treatment, the A549 cells displayed morphological characteristics associated with cell autophagy. Ad-GFP-LC3 was used to detect GFP-LC3 translocation in A549 cells. GFP-LC3 exhibited diffuse expression in untreated cells but high punctate expression in BOS-93-treated cells. Western blot analysis revealed accumulation of autophagosome-bound LC3-II. This phenomenon was reversed when cells were treated with 3-MA, an autophagy inhibitor, which indicated that BOS-93 induces autophagy of A549 cells.
It has been reported that the molecular machinery of autophagy is largely directed by a number of Atgs. For example, previous studies have demonstrated that Atg 14 and beclin-1 are essential for the formation of autophagosomal precursor (9, 14) . In the present study, the expression of Atg14 and beclin-1 were determined using western blot analysis. the data demonstrated that BOS-93 treatment induced upregulation of Atg14 and beclin1. Furthermore, combining 3-MA with BOS-93 resulted in a significant decrease in the expression of Atg14 and beclin-1 compared with BOS-93 cultured alone, suggesting that BOS-93 induced autophagy in A549 cells.
Given that both apoptosis and autophagy could be induced by BOS-93 in A549 cells, their mutual association was investigated. Several studies have reported that chemotherapeutic drugs can induce both apoptosis and autophagy in cancer cells (10, 17) . Autophagosome formation is regulated by the mTOR pathway, a major nutrient sensor (9) . The present study demonstrated that, upon BOS-93 treatment, PI3K, Akt and mTOR phosphorylation was reduced in A549 cells, indicating downregulation of the PI3K/Akt/mTOR pathway.
MAPK signal pathways (including p38 MAPK and ERK1/2) are associated with the transduction of extracellular stimuli signals into cells and their nuclei and initiation of cellular biological reactions such as cell proliferation, differentiation, transformation and apoptosis (31, 32) . ROS can act as a second messenger to activate the MAPK signaling pathway (23) . In addition, it is well known that p38 is closely associated with the initiation of apoptosis and the cell cycle (33) . ERK1/2 is mainly activated by phosphorylation of various growth factors and oxidative stress, and it is closely associated with cell proliferation and differentiation (34) . In the present study, it was demonstrated that BOS-93 treatment triggered ROS generation and increased phosphorylation of p38 and ERK, suggesting that the p38/ERK signaling pathway was associated with BOS-93 induced apoptosis and autophagy in A549 cells.
In conclusion, the present study demonstrated that BOS-93 could induce G0/G1 arrest, apoptosis and autophagy in A549 cells, and that BOS-93 could inhibit PI3K/Akt/mTOR and activate the MAPK pathway (Fig. 8) . Furthermore, BOS-93 could also exert anti-tumor activity in vivo. Therefore, the findings indicated that BOS-93 may display excellent effects on human lung cancer cells and act as a multi-target anti-cancer drug due to its ability of leading to apoptosis and autophagy.
